Obesity is a significant global health challenge that requires lifestyle changes and
effective pharmacological treatments to overcome. Human glucagon-like peptide 1
(GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity
treatment option. Additionally, oral GLP-1 formulations represent a groundbreaking
advance in obesity treatment, offering greater patient comfort and adherence to
expand the therapeutic market.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.